

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40281 A2**

- (51) International Patent Classification<sup>7</sup>: C07K 14/31 (74) Agent: VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).
- (21) International Application Number: PCT/EP00/12299
- (22) International Filing Date: 1 December 2000 (01.12.2000) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 99204093.1 2 December 1999 (02.12.1999) EP
- (71) Applicant (*for all designated States except US*): THROMB-X N.V. [BE/BE]; Leopold-I-straat 1, bus 21, B-3000 Leuven (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): WARMERDAM, Petronella, Adriana, Maria [NL/BE]; Ploegstaart 1, NL-3010 Kessel-Lo (BE). PLAISANCE, Stéphane, Daniel, Noël, Georges, Henri [BE/BE]; A. Woutersstraat 61, B-3012 Wilsele (BE). COLLEN, Désiré, José [BE/GB]; 28 Collingham Gardens, London SW5 0HN (GB). DE MAEYER, Marc, Cyriel, Hilda [BE/BE]; Keienveld 2, B-1702 Groot-Bijgaarden (BE).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/40281 A2

(54) Title: METHOD FOR REDUCING THE IMMUNOGENICITY OF HETEROLOGOUS PROTEINS BY ELIMINATION OF T-CELL EPITOPES

(57) Abstract: The present invention provides a method for reducing the immunogenicity of a peptide or protein, which method comprises the steps of designing a series of overlapping test peptides each having an amino acid sequence that corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced; identifying which of the test peptides of the series comprises one or more T-cell epitope(s); modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s); repeating some of the steps with the modified test peptides until one or more of the T-cell epitopes originally comprised therein are significantly reduced or eliminated; modifying the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides to produce a modified peptide or protein. The invention also relates to the modified peptides and proteins thus obtained.

BEST AVAILABLE COPY

METHOD FOR REDUCING THE IMMUNOGENICITY OF HETEROLOGOUS  
PROTEINS BY ELIMINATION OF T-CELL EPITOPES

The present invention relates to a method for  
5 reducing the immunogenicity of a peptide or protein by  
elimination of T-cell epitopes. The invention furthermore  
relates to a method for producing proteins and peptides  
having a reduced T-cell reactivity and to the peptides  
and proteins, in particular staphylokinase variants, thus  
10 obtained. The invention also relates to the use of these  
modified peptides and proteins in therapy, diagnosis and  
prophylaxis.

An immune response involves, firstly,  
recognizing foreign material (pathogen/antigen) and  
15 secondly, mounting a reaction to eliminate it. Broadly  
speaking, two types of reactions can be triggered; an  
innate or non-specific response and an adaptive or highly  
antigen-specific response. It is the latter reaction that  
improves with each successive encounter with the same  
20 foreign material. The immune system remembers the foreign  
material, and deals with it more promptly, generating a  
life-long immunity following initial exposure.

Lymphocytes play a central role in all adaptive  
immune responses, since they specifically recognize  
25 individual pathogens/antigens, whether they come from  
inside host cells or outside in the tissue fluids or  
blood. In fact, there are several different types of  
lymphocytes, but they fall into two basic categories, T-  
lymphocytes (or T-cells) and B-lymphocytes (or B-cells).

30 B-cells combat antigens and pathogens and their  
products by releasing specific antibodies.

T-cells can be divided in different types and  
display a wider range of activities. The so-called  
cytotoxic T-cells are responsible for the destruction of  
35 host cells, which have become infected with viruses or  
other pathogens. T helper cells can interact with  
phagocytes and help to destruct pathogens. Other T helper

cells are involved in the control of B-lymphocyte development and antibody production.

Each B-cell is genetically programmed to encode a unique surface receptor specific for a particular antigen. Having recognized its specific antigen, the B-cells can proliferate and differentiate into plasma cells, which produce large amounts of the receptor molecule in a soluble form, known as the antibody.

While B-lymphocytes recognize conformational epitopes (3-D surface structure) on native antigens, T-cells recognize linear amino acid sequences (T-cell epitopes). But they can only do so, when the T-cell epitope is presented on the cell surface of other cells by the so-called human histocompatibility leucocyte antigens (HLA) molecules. The antigen is not presented by the HLA molecules as intact proteins, but rather as processed peptides non-covalently bound in their peptide-binding groove. This processing and presentation can be done by specialized antigen presenting cells (APC), which are capable of stimulating T-cells, or by infected cells, which then become a target for cytotoxic T-cells. The T-lymphocytes can recognize these HLA-peptide complexes by virtue of a specific receptor, called the T-cell receptor (TCR). Each TCR is unique, it recognizes a specific peptide bound in the groove of a particular HLA-molecule. Upon recognition, the specific T-cell receives an activation signal, then a secondary signal is needed to induce a T-cell response, which includes proliferation and cytokine production.

If an individual encounters an antigen, and the immune system answers with a humoral response, a series of cellular and molecular interactions occur in an orderly sequence. The first interaction involves antigen-specific T-cells and APC. Its outcome largely dictates the subsequent course of events. A sufficient number of T-helper cells needs to be triggered appropriately. Specific T-cells then respond with proliferation and cytokine secretion.

Subsequently, these activated T-helper cells interact with specific B-cells that present antigen to them. This B-T-cell contact in combination with the secreted cytokines, will activate the B-cells and  
5 subsequently induce proliferation and differentiation into plasma cells. In turn, they produce antibodies, and depending on the T-cell signals they received, differentiate further by class switching, affinity maturation and the development of an immunological  
10 memory.

Thus, for secondary or subsequent antigen encounter, a larger number of antigen-specific B-cells is present, making them the major type of APC, and importantly induce a shorter circuit in the immunological  
15 response. However, if the T-helper cells are not triggered simultaneously, a form of immunological tolerance can develop, and no immunological events will follow.

Based on these considerations, the present  
20 inventors contemplated that the elimination of functional T-cell epitopes will also have a great influence on the induction of a humoral response. If fewer or no specific T-cells are triggered, because specific peptides can no longer be efficiently presented, B-lymphocytes will be  
25 hampered to mature and, consequently, the antibody production will be abrogated.

It is thus a first object of the present invention to provide a way of reducing the T-cell based immunogenicity of peptides and proteins.

30 This object is achieved by a method for reducing the immunogenicity of a peptide or protein, which method comprises the steps of:

a) designing a series of overlapping test peptides each having an amino acid sequence that  
35 corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced;

b) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);

c) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell  
5 epitope(s);

d) repeating step b) and optionally step c) with the modified test peptides until one or more of the T-cell epitopes originally comprised therein are significantly reduced or eliminated;

10 e) modifying the amino acid sequence of the peptide or protein the immunogenicity of which is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides to produce a modified peptide or protein.

15 The above described method refers to the minimum amount of steps necessary. It is possible to make suitable modifications to test peptides in only one round. In case such modifications are sufficient this will appear in the repetition of step b). Such  
20 modifications can then be transferred to the peptide or protein of which the immunogenicity is to be reduced. It is however also possible to find upon repetition of step b) that further modifications are necessary. Step c) might refer also to more rounds of modification without  
25 an intermediate check for T-cell epitopes as in step b).

In addition to the above steps, there are further preferred steps that can be part of the method. It is for example possible to test the modified test peptides or the modified peptide or protein for their  
30 potential to activate T-cells and induce proliferation of T-lymphocytes as present in the circulation of humans (PBMC test). This represents an ex vivo situation and gives insight in the effect of the modifications on the in vivo immunogenicity.

35 Furthermore, it is possible to do the whole process of identification, modification (steps b) and c)) and optional PBMC testing all over again with the already modified peptide or protein.

The step of modifying the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides can for example be performed by expression of a DNA sequence encoding the modified amino acid sequence in a suitable host.

The identification of peptides comprising a T-cell epitope can be performed in various ways. In one embodiment use is made of a functional T-cell assay in which proliferation of one or more T-cell clones after stimulation of the T-cell clone(s) with one of the test peptides means that the said test peptide comprises a T-cell epitope. In a second embodiment use is made of a functional T-cell assay in which proliferation of one or more T-lymphocytes as present in the circulation of humans (PBMC) after stimulation of the PBMC with one of the test peptides means that the said test peptide comprises a T-cell epitope. In these embodiments actual peptides are used that are synthesized on the basis of the amino acid sequence of the peptide or protein of which the T-cell based immunogenicity is to be reduced.

Alternatively, the identification of peptides comprising a T-cell epitope is performed by determining the interaction energy of the test peptide with the binding groove of one or more HLA-DR haplotypes by means of computer modeling, in which test peptide(s) are identified as comprising a T-cell epitope when according to their interaction energy they fit into the HLA-DR binding groove. In this embodiment, the peptides are not actually synthesized but virtual peptides are used.

It is preferred according to the invention that the identification of peptides comprising a T-cell epitope is performed by a combination of the following tests:

a) a functional T-cell assay in which proliferation of one or more T-cell clones' after stimulation of the T-cell clone(s) with one of the test

peptides means that the said test peptide comprises a potential T-cell epitope, and/or

b) a functional T-cell assay in which proliferation of one or more T-lymphocytes as present in the circulation of humans (PBMC) after stimulation of the PBMC with one of the test peptides means that the said test peptide comprises a T-cell epitope; and

c) determining the interaction energy of the said test peptide with the binding groove of one or more HLA-DR haplotypes by means of computer modeling, in which the test peptide is identified as comprising a potential T-cell epitope when according to its interaction energy it fits into the HLA-DR binding groove, wherein a test peptide is considered to comprise a T-cell epitope if it is identified in test a) and/or b) and c).

In this embodiment, one test is a check for the other. Only a T-cell assay can give information on the functionality of the T-cell epitope. A peptide that theoretically fits the HLA binding groove may not lead to T-cell proliferation.

The present invention thus deals with the identification of functional human T-cell epitopes (immunogenic regions) in proteins, preferably based on the combined results of computer modeling of test peptides in the HLA-DR binding groove and human T-cell analysis. More specifically, the present invention relates to a method calculating the interaction energy between two proteins/peptides.

Step d) of the above described method of the invention deals with the re-evaluation of newly introduced epitopes in the modified protein, preferably by combining the results of computer modeling of the modified test peptides in the HLA-DR binding groove and human T-lymphocyte screening with the modified protein.

The purpose of the method described above is the reduction of the immunogenicity of foreign proteins by elimination of the identified immunogenic regions. The invention according to a further aspect thereof relates

to methods to remove the immunogenic regions by either deletion or insertion of the coding sequences, or by humanization of the coding sequences, or by in vitro mutagenesis of the coding sequences to replace one or  
5 more codons for wild type amino acids by a codon for another residue, or by making the immunogenic regions more sensitive for the proteolytic endosomal enzymes. The latter type of modification can influence the manner in which the T-cell epitope is presented on antigen  
10 presenting cells. In addition, modification of immunogenic regions to make them more sensitive for proteolytic enzymes can result in the generation of peptides that are too short to fit into and bind the HLA-DR groove. It is known that 9 amino acids fit in the  
15 groove, but that a minimum of 11 amino acids is necessary for binding. Changing the position of the target sites for endogenous proteolytic enzymes may lead in vivo to the production of shorter peptides that do no longer bind the HLA-DR groove.

20           The present invention also relates to methods for producing modified peptides and proteins of the invention by preparing a DNA fragment encoding at least the part of the structural information of the peptide or protein that provides for its biological activity;  
25 mutating the DNA fragment to eliminate therefrom the coding information for one or more T-cell epitopes; cloning the mutated DNA fragment in a suitable vector, transforming or transfecting a suitable host cell with the vector, and culturing the host cell under conditions  
30 suitable for expressing the DNA fragment.

More specifically, the invention provides a method for producing a peptide or protein having a reduced immunogenicity in comparison to wild type peptide or protein, comprising the following steps:

35           a) providing a DNA sequence encoding at least the amino acid sequence of the peptide or protein that provides for the biological activity thereof;

b) identifying one or more of the T-cell epitopes comprised in the amino acid sequence of the wild type peptide or protein by:

1) designing a series of overlapping test  
5 peptides each having an amino acid sequence that corresponds with part of the amino acid sequence of the peptide or protein;

2) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);

10 3) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);

4) repeating step 2) and optionally step 3) with the modified test peptides until one or more of  
15 the T-cell epitopes originally comprised therein are significantly reduced or eliminated;

c) modifying the DNA sequence to introduce the modifications to the T-cell epitope(s) in the amino acid sequence encoded thereby;

20 d) introducing the DNA sequence into a host organism;

e) culturing the host organism under conditions allowing expression of the modified peptide or protein; and

25 f) isolating the peptide or protein having a reduced immunogenicity from the host organism.

In the above methods further steps may be incorporated as described above for the method for reducing the immunogenicity of a peptide or protein.

30 The peptides and proteins that can be produced according to the invention and that have a reduced T-cell based immunogenicity as compared to their wild type counterparts are novel and thus also part of this invention. The invention is applicable to reduce the T-  
35 cell based immunogenicity of all types of proteins and glycoproteins, either from human origin or originating from plants, micro-organisms or animals. Targets are also fusion proteins consisting in part of a protein from the

host in which the protein is produced and in part of the desired protein. Other targets for the method of the invention are humanized proteins.

When a protein or peptide is of human origin it  
5 can still be immunogenic when administered to a human. An example of this is the administration to a human individual of a protein for which the individual is deficient. The individual's body does not recognize the protein as "self", even though it may be of human origin,  
10 and will develop an immune response. Another example is when a protein of human origin is no longer entirely human, such as human interferon- $\alpha$  produced in E.coli which is not glycosylated and found to be immunogenic, or when proteins of human origin are modified to obtain  
15 better properties, such as an increased solubility. In particular, the invention is useful for lowering the T-cell based immunogenicity of non-human proteins, such as staphylokinase, streptokinase or antibodies from other species or fragments thereof, or chimeric proteins, or  
20 fusion-proteins, or de-novo proteins for the diagnostics or treatment of human disease.

All such peptides and proteins that are in some way or for some reason immunogenic when administered to a human subject may be made less immunogenic by the method  
25 of the invention. To illustrate this invention use is made in the examples of staphylokinase. The invention is however far more general applicable as has been explained above and encompasses all proteins and peptides that are made less immunogenic in this manner. According to a  
30 particular embodiment of the proteins of the invention, staphylokinase derivatives are provided that have a reduced T-cell based immunogenicity as compared to wild type staphylokinase.

While modifying a protein or peptide for  
35 reducing its immunogenicity care should be taken that the biological activity of the protein or peptide is not severely decreased or even lost. It is thus preferred that after producing a modified protein or peptide, its

biological activity is tested. Tests for determining the activity of the protein or peptide are usually available in the state of the art.

According to a further aspect thereof, the invention relates to the modified peptide or protein for use in treatment, diagnosis or prophylaxis and to the use of a modified peptide or protein for the preparation of a pharmaceutical composition for treatment, diagnosis or prophylaxis of a human subject.

10 The present invention according to a further aspect thereof relates to pharmaceutical compositions comprising at least one of the less immunogenic derivatives according to the invention together with a suitable excipient, for diagnostics or treatment in  
15 humans. Such compositions may be prepared by combining (e.g. mixing, dissolving etc.) the active compound with pharmaceutically acceptable excipients of neutral character (such as aqueous or non-aqueous solvents, stabilizers, emulsifiers, detergents, additives). The  
20 concentration of the active ingredient in a therapeutic composition may vary widely, depending on the character of the disease and the mode of administration.

The present invention relates to so-called "T-cell based immunogenicity" which means that according to  
25 the invention T-cell epitopes are identified, characterized and modified. The invention does not relate to general methods for the identification, production and use of staphylokinase derivatives showing a reduced antigenicity as compared to wild type staphylokinase,  
30 based on the elimination of B-cell epitopes as previously described in US-5,695,754, US-5,951,980 and WO-9940198. These methods are totally distinct from and are not the subject of the present invention, although the antigenic regions (recognized by antibodies and B-cells) described  
35 in these patent publications may (partly) overlap by serendipity with immunogenic regions involved in the T-cell response (T-cell recognition).

In a particular embodiment of the invention, the modified peptide or protein is staphylokinase. Staphylokinase, a protein produced by certain strains of Staphylococcus aureus, which was shown to have 5 fibrinolytic properties more than 5 decades ago appears to constitute a potent thrombolytic agent in patients with acute myocardial infarction. The staphylokinase gene has been cloned from the bacteriophages sakØC (Sako and Tsuchida, 1983) and sak42D (Behnke and Gerlach, 1987) as 10 well as from the genomic DNA (sakSTAR) of a lysogenic Staphylococcus aureus strain (Collen et al., 1992). The staphylokinase gene encodes a protein of 163 amino acids, with amino acid 28 corresponding to the NH<sub>2</sub>-terminal residue of full-length mature staphylokinase. The mature 15 protein sequence of the wild type variant SakSTAR is represented in Fig. 1. Only four nucleotide differences were found in the coding regions of the sakØC, sak42D and sakSTAR genes, one of which constituted a silent mutation.

20 More in particular the invention relates to staphylokinase variants in which one or more of the following immunogenic regions are modified such that the T cell epitopes contained therein are eliminated:

25 1-SSSFDKGKYKKGDDASY-17,  
16-SYFEPTGPYLMVNVTVGV-32,  
56-TKEKIEYYVEWALDATA-72,  
71-TAYKEFRVVELDPSAKI-87,  
106-ITEKGFVVPDLSEHIKN-122, and  
120-IKNPGFNLITKVVIEKK-136.

30 Furthermore, the invention relates to staphylokinase variants with reduced T-cell reactivity as compared to wild type staphylokinase, but retaining its biological activity, which variants have the amino acid sequence depicted in Figure 1 with one or more of the 35 following amino acid substitutions in one or more of the following immunogenic region:

a) in the immunogenic region comprising SakSTAR residues 16-32 the substitutions Y17L; F18L; F18E; E19D; P20Y, Y24A; P20Y, Y24S; G22S; G22P, P23G; N28S;

b) in immunogenic region comprising SakSTAR  
5 residues 71-82 the substitutions F76W, V79Y, D82A; R77A, E80A; R77S, E80S; R77A, E80A, D82A; K74Q, R77S, E80S; K74Q, R77S, E80S, D82G; K74Q, R77S, E80S, D82A; K74Q, R77S, E80A, D82A; K74Q, R77A, E80S, D82A; K74Q, R77S, E80S, D82S; V79Y, D82A;

10 c) in immunogenic region comprising SakSTAR residues 106-122 the substitutions V112T; V112S; D115N; E118S; H119A; H119S; V89L, L116Y; V89L, L116T; V112T, H119S; V112T, H119A; V112T, E118S, H119S;

d) in immunogenic region comprising SakSTAR  
15 residues 120-136, the substitution K130Y.

It is preferred that such staphylokinase variants have a combination of one or more of the mutations listed above, in particular one of the following combination of mutations V112T, H119S, K130Y;  
20 R77E, E134R; V29L, L127V; K74Q, R77E, E80S, D82S, E134R; R77S, E80S, V112T, H119S; R77S, E80S, V112T, H119S, K130Y; R77A, E80A, V112T, H119S; R77A, E80A, V112T, H119S, K130Y; K74Q, R77S, E80S, V112T, H119S; K74Q, R77S, E80S, V112T, H119S, K130Y; K74Q, R77S, E80S, D82S, V112T,  
25 H119S; K74Q, R77S, E80S, D82S, V112T, H119S, K130Y.

Preferred staphylokinase variants are selected from the group consisting of SakSTAR(P20Y, Y24A), SakSTAR(P20Y, Y24S), SakSTAR(E19D), SakSTAR(Y17L), SakSTAR(F18L), SakSTAR(F18E), SakSTAR(G22S),  
30 SakSTAR(G22S, P23G), SakSTAR(N28S), and SakSTAR(V29L, L127V), SakSTAR(R77E, E134R), SakSTAR(K74Q, R77E, E80S, D82S, E134R), SakSTAR(K74Q, R77E, E80S, D82S, V112T, H119S, E134R), SakSTAR(K74Q, R77E, E80S, D82S, V112T, H119S, E134R, K130Y); SakSTAR(R77S, E80S, V112T, H119S),  
35 sakSTAR(R77S, E80S, V112T, H119S, K130Y), SakSTAR(R77A, E80A, V112T, H119S), SakSTAR(R77A, E80A, V112T, H119S, K130Y), sakSTAR(K74Q, R77S, E80S, V112T, H119S), SakSTAR(K74Q, R77S, E80S, V112T, H119S, K130Y),

sakSTAR(K74Q, R77S, E80S, D82S, V112T, H119S),  
SakSTAR(K74Q, R77S, E80S, D82S, V112T, H119S, K130Y),  
SakSTAR(V112T, H119A), SakSTAR(V112T, H119S),  
SakSTAR(V112T, E118S, H119S), SakSTAR(V112T, H119S,  
5 K130Y), SakSTAR(V112T), SakSTAR(V112S), SakSTAR(H119A),  
SakSTAR(H119S), SakSTAR(V89L, L116Y), SakSTAR(V89L,  
L116T), SakSTAR(V112T), SakSTAR(V112S), SakSTAR(D115N),  
SakSTAR(E118S), SakSTAR(K130Y).

It was found that a staphylokinase variant in  
10 which at least residue K130 of the wild type amino acid  
sequence is replaced by a Y is particularly preferred.

To test whether the variants produced still  
retain their thrombolytic activity a test can be used as  
described in Collen et al., (1996b).

15 The staphylokinase variants can be used in  
treatment, diagnosis or prophylaxis. The invention  
furthermore relates to the use of a staphylokinase  
variant for the preparation of a pharmaceutical  
composition for treatment, diagnosis or prophylaxis of a  
20 human subject and to a pharmaceutical composition  
comprising a staphylokinase variant together with a  
pharmaceutically acceptable carrier, diluents or  
excipient.

The invention will be further elucidated in the  
25 examples that follow, using staphylokinase as a model of  
an immunogenic non-human protein with therapeutic  
potential, but this example is not intended to limit the  
scope of the invention, since several alternative  
applications will be obvious for the persons skilled in  
30 the art. Thus, the same methodology could be applied to  
the de-immunization of other non-human or human proteins.

In the examples reference is made to the  
following figures:

**Figure 1.** Primary sequence of staphylokinase  
35 (SakSTAR). The amino acids are given in the one letter  
code: A, alanine; D, aspartic acid; E, glutamic acid; F,  
phenylalanine; G, glycine; H, histidine; I, isoleucine;  
K, lysine; L, leucine; M, methionine; N, asparagine; P,

proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophane; and Y, tyrosine.

**Figure 2.** Minimal epitopes analysis of a representative panel of region(71-87)-specific T-cell clones. The T-cell clones were cultured with antigen presenting cells and SakSTAR peptide 71-TAYKEFRVVELDPSAKI-87, 15 peptides with single alanine substitutions in the region 71-87, and two 11-mer peptides (S1, S2), as indicated. If the proliferation of a T-cell clone with the corresponding peptide was found comparable to that induced by the wild-type peptide (first column), a dark fill is plotted. A light gray fill indicates a significantly lower proliferation value compared to that with the same concentration of the SakSTAR-(71-87) peptide, whereas a white box represents no detectable proliferation for the combination.

**Figure 3. a:** Modeling of 13 peptides (11-mer) encompassing the immunogenic region in SakSTAR. The non-bonded interaction energy (kcal/mol) of each peptide with the HLA-DR1 structure is plotted. Longer bars denote a stronger HLA-DR1 binding. The two selected peptides, S1 and S2, are shown in black bars. **b:** Modeled structure of the representative peptide S2 in ribbon representation (Koradi et al., 1996). The S2 peptide is shown in light gray, HLA-DR1  $\alpha$ - and  $\beta$ -chain are color coded respectively in middle and dark gray. The side chain of  $\beta$ -chain R71 interacting with peptide residue D82 is highlighted.

**Figure 4.** Alanine scanning experiment of the S1 (a,b,c) and S2 (d,e,f) peptide in the context of HLA-DR7. **a,d:** The loss of interaction energy (kcal/mol) for each alanine mutant as compared to the wild type peptide is plotted. Longer bars mean that the corresponding peptide binds less well in the peptide-binding groove. **b,e:** Bar graph of the loss of contact area ( $\text{\AA}^2$ ) for the same series of peptides relative to the wild-type SakSTAR peptide. **c,f:** Plot of the solvent-accessible and buried surface area for each residue of the peptide bound in the groove. Positive values represent side chains exposed to the

solvent in the context of the complex, which are potentially available for T-cell recognition. Negative values indicate the extent of burying in the corresponding HLA-DR pockets, numbered 1 to 9.

5                   **Figure 5.** Proliferation responses of staphylokinase (SakSTAR-myc)-primed PBMC to SakSTAR-myc, the SakSTAR peptide 71-87 or peptide derivatives thereof. PBMC from ten region-(71-87)-immunoreactive donors were primed for SakSTAR-myc and re-stimulated with irradiated  
10 CD3-depleted autologous PBMC and with no antigen, SakSTAR-myc, wild type SakSTAR(71-87) peptide TAYKEFRVVELDPSAKI, five single mutation(71-87) peptides (TAYAEFRVVELDPSAKI, TAYKA FRVVELDPSAKI, TAYKEFAVVELDPSAKI, TAYKEFRVVALDPSAKI, TAYKEFRVVELAPSAKI), and four multiple  
15 mutation(71-87) peptides (TAYKEFAVVALDPSAKI, TAYKEFAVVALAPSAKI, TAYQEFSVLSLSPSAKI, TAYAAFAVVALAPSAKI). The cellular response is plotted as stimulation index. Each individual spot represents a cellular response from a single donor to the indicated antigens/peptides.

20                   **Figure 6.** Minimal sequence requirements of epitope-specific T-cell clones. The T-cell clones were cultured with APC and according to their specificity with SakSTAR peptides 16-SYFEPTGPYLMVNV TGV-32 (16-26, and 23-33), 56-TKEKIEYYVEWALDATA-72 (61-71), 71-  
25 TAYKEFRVVELDPSAKI-87 (72-82, and 75-85), 106-ITEKGFVVPDLSEHIKN-122 (110-120), or 120-IKNPGFNLITKV VIEKK-136 (124-134) combined with single alanine substitution peptides derived from the original SakSTAR peptide. The number of analyzed clones is plotted  
30 in the right column. The % of proliferating clones is given for an alanine-substituted peptide at each residue. A dark fill is plotted if more than 75% of the epitope-specific T-cell clones proliferated when the indicated residue was changed into an alanine. A medium gray fill  
35 indicates that an alanine change affected less than 25% of the epitope-specific T-cell clones in their proliferative capacity. A light gray box indicates that only 25-50% of the epitope-specific T-cell clones could

proliferate, and a white box represents a proliferative response of less than 25% of the epitope-specific T-cell clones. Thus, the whiter the box, the less T-cell clones proliferated to a peptide with an alanine substitution at the indicated position. In summary, a white box indicates that the residue is important for HLA-DR binding or TCR recognition and will be the target for mutagenesis experiments.

10

### EXAMPLES

#### **EXAMPLE 1**

##### Isolation of human staphylokinase-specific T-cell clones

Wild type recombinant staphylokinase (SakSTAR) was expressed and purified as previously described (Collen et al., 1996a; Schlott et al., 1994), followed by an additional size exclusion chromatography step using a superdex 75 column (Pharmacia, Uppsala, Sweden). The purity of SakSTAR was determined to be greater than 98%, as judged by SDS-PAGE analysis.

Normal healthy individuals were HLA-DR typed by the Inno-LiPa method (Buyse et al., 1993) (Innogenetics, Gent, Belgium) and their peripheral blood mononuclear cells (PBMC) isolated according to standard procedures using Ficoll-Hypaque density gradient centrifugation. Ten healthy donors were selected representing >95% of the major HLA-DR haplotypes in the USA and Europe.

For the cloning of SakSTAR-specific T-cell clones, approximately  $15 \times 10^6$  PBMC from each donor were stimulated with an optimal concentration of SakSTAR for 7-9 days. The visible T-cell clones were harvested under the microscope, and individually re-stimulated in a 96-well flat-bottom plate with autologous PBMC as antigen presenting cells (APC). These wells were supplemented on day 1 with 20U/ml recombinant human interleukin-2 (IL-2) (Boehringer Mannheim, Mannheim, Germany) and allowed to grow for 8-11 days. Re-stimulation was repeated every 8-11 days under the same conditions. After 3 to 6 passages,

autologous PBMC were replaced by autologous Epstein Barr Virus (EBV)-immortalized B-cell lines as antigen presenting cells.

In order to obtain autologous APC which could  
5 be maintained for longer periods of time, EBV was isolated from Marmoset B95-8 cells (ATCC#CRL1612) according to standard centrifugation and filtration procedures (Miller and Lipman, 1973).

Concentrated PBMC from the T-cell clone donors  
10 were infected for 2 hours with EBV containing supernatants. They were subsequently diluted and cultured at  $5 \cdot 10^6$  PBMC/ml, in RPMI1640 supplemented with 10% FCS, 10  $\mu$ g/ml gentamycin and 1  $\mu$ g/ml cyclosporin A. The B-lymphocytes that were transformed with EBV could now be  
15 maintained in culture and stored under liquid nitrogen. These procedures resulted in the isolation of over 100 SakSTAR specific T-cell clones (CD3<sup>+</sup>, CD4<sup>+</sup>).

## EXAMPLE 2

### 20 Localization and characterization of immunogenic regions in staphylokinase by functional T-cell assays

To identify immunogenic regions on the SakSTAR molecule, the isolated T-cell clones were tested for their specificity using SakSTAR-derived peptides. In  
25 total 25 peptides 17 residues in length, each overlapping 12 residues were synthesized using a fluorenylmethoxycarbonyl-protected amino acid coupling procedure (Hiemstra et al., 1997). Each individual T-cell clone was tested for its specificity by co-culturing T-cells,  
30 Mitomycin C-treated autologous EBV-B-cells and antigen or the appropriate peptide for 4 days. Subsequently, the T-cell clones were pulsed for 24 hours with BrdU, harvested and analyzed for their BrdU content. Proliferation after stimulation with a specific peptide was found positive,  
35 if the proliferation was at least three times the background, revealing the specificity of that particular T-cell clone.

These assays revealed the presence of 6 distinct immunogenic regions within the SakSTAR molecule. The following peptides (SakSTAR residue number and sequence) were found to be immunogenic:

- 5        1-SSSFDKGKYKKGDDASY-17,  
         16-SYFEPTGPYLMVNVTVG-32,  
         56-TKEKIEYYVEWALDATA-72,  
         71-TAYKEFRVVELDPSAKI-87,  
         106-ITEKGFVVPDLSEHIKN-122, and  
10       120-IKNPGFNLITKVVEKK-136.

### EXAMPLE 3

#### Localization and characterization of human T-cell epitopes in staphylokinase by computer modeling of 15 peptides in the HLA-DR binding groove

The total amino acid sequence of SakSTAR was threaded as 11-mer sequences, shifting one residue at the time, through the HLA-DR binding groove of the major haplotypes, and the interaction energy of all these  
20 combinations were calculated, using the dead-end elimination theorem (DEE) (De Maeyer et al., 1997; Desmet et al., 1992), which is embedded in the Brugel molecular modeling package (Delhaise et al., 1984).

The energy function (Wodak et al., 1986) used,  
25 comprises the usual terms for bond stretching, bond-angle bending, a periodic function for the torsion-angles, a Lennard-Jones potential for the nonbonded atom pairs, a 10-12 potential for hydrogen bonds, and a Coulombic function for charged atoms. The dielectric constant has  
30 been set to  $r_{ij}$ , the distance between the  $i$  and  $j$  atoms (Warshel and Levitt, 1976). The energy parameters are derived from the CHARMM library (Brooks et al., 1983). All modeling uses the above energy function in the presence of all explicit hydrogen atoms, the carboxylate  
35 and imidazole groups were not protonated.

These calculations predicted that SakSTAR contained several T-cell epitopes, which could fit in most HLA-DR haplotypes.

**EXAMPLE 4**Identification of T-cell epitopes in SakSTAR

Combining the specificity data of the isolated T-cell clones with the predicted T-cell epitopes obtained from computer modeling yielded largely overlapping results. The identified SakSTAR T-cell epitopes are summarized in Table I.

Table I Overview of the identified T-cell epitopes in staphylokinase; SakSTAR

Position in Staphylokinase	Residues in Staphylokinase
6-17	KGKYKKGDDASY
16-26	SYFEPTGPYLM
23-33	PYLMVNVGTGVD
43-53	HYVEFPIKPGT
61-71	EYYVEWALDAT
65-75	EWALDATAYKE
72-82	AYKEFRVVELD
75-85	EFRVVELDPSA
90-100	TYYDKNKKKKEE
110-120	GFVVPDLSEHI
124-134	GFNLITKVVIE

The numbers represent the residue positions in the mature staphylokinase molecule, the amino acids are represented by a single letter code.

The SakSTAR sequences 43-HYVEFPIKPGT-53 and 90-TYYDKNKKKKEE-100 were calculated to fit in most HLA-DR haplotypes, however, no T-cell clones were isolated that proliferated to peptides which included these sequences. The remaining 9 identified epitopes were found to be

functional, since epitope-specific T-cell clones were isolated.

#### EXAMPLE 5

##### 5 Determination of the residue preference at each position in the HLA-DR peptide-binding groove

As described above computer modeling allows the identification of amino acid sequences in a protein with good interaction energy with the binding groove of the  
10 HLA-DR molecule, which implies T-cell stimulating capability and therefore immunogenicity.

The same computer technique may be used to model sequences that are less favorable for binding at each position in the peptide-binding groove. The DEE  
15 implementation allows the calculation of the interaction energy of the complete enumeration of all sequence combinations for a 9-mer peptide bound in the groove. From these results, the skilled person will be able to extract an interaction preference matrix with the  
20 calculation method as described in Example 3. This matrix contains for each amino acid at each position in the peptide the interaction energy with the HLA-DR molecule. This interaction energy is interpreted as the likelihood for an amino acid to be found in a binding peptide.

25 Therefore, less well binding residues may possibly lower the affinity or even disrupt the binding of the peptide in the HLA molecule. This matrix was calculated for each HLA-DR haplotype. If the DR restriction for an immunogenic region is known, these  
30 tables can be consulted to design alternate sequences, which bind less well in the groove, but do not interfere with the 3-D folding of the protein. Since the different DR matrices share a common pattern, a generalized matrix can be assembled. In case the DR restriction is not  
35 known, this generalized matrix can be consulted.

**EXAMPLE 6**Identification of critical residues in an immunogenic region by screening with a T-cell clone library

Interestingly, the peptide with sequence  
5 71-TAYKEFRVVELDPSAKI-87 of SakSTAR stimulated T-cell clones isolated from 9 of 10 donors, suggesting a promiscuous character. In order to define the minimal epitope for each individual T-cell clone, SakSTAR region(71-87)-peptide derivatives, each one with a  
10 different single alanine substitution were used in T-cell proliferation assays. A representative panel is shown in Fig. 2.

Alanine substitution at positions F76, R77, V78, or E80, abolished proliferation of the majority of  
15 the region(71-87)-specific T-cell clones. Side chain removal by mutation into an alanine residue of K74 or D82 affected the proliferative capacity of approximately half of the region(71-87)-specific T-cell clones, whereas a minority of them was found sensitive for an alanine  
20 substitution of residues Y73, E75, V79, L81 or P83.

**EXAMPLE 7**Analysis of an immunogenic region by computer analysis

T-lymphocyte proliferation requires both  
25 appropriate peptide presentation and T-cell receptor recognition. Consequently, T-cell assays alone cannot discriminate between HLA-DR-binding and receptor-facing residues within a peptide. To unravel the molecular basis of this ambiguity, a computer modeling approach was used  
30 starting from available HLA-DR1 X-ray coordinates (Brown et al., 1993). The extended immunogenic SakSTAR sequence 67-ALDATAYKEFRVVELDPSAKIEV-89 was threaded as 11-mer peptides, each shifted by a single residue, through the HLA-DR1 peptide-binding groove. The main-chain atoms of  
35 both HLA-DR and the peptide were kept fixed, while all side chains were placed in the global minimum energy conformation using the dead-end elimination theorem (Desmet et al., 1992). Modeling in the context of the

other haplotypes, yielded essentially the same results. The interaction energy for each peptide with the groove was calculated, and is represented in Fig.3a.

Two strong binding sequences AYKEFRVVELD (S1; 5 SakSTAR residues 72-82) and EFRVVELDPSA (S2; SakSTAR residues 75-85) were identified (Fig.3a; black bars), placing the second residue of both sequences in HLA-DR pocket 1. A typical model of the S2 peptide within the binding groove is shown in Fig.3b.

10 The extent of both solvent exposure and burying of each residue of the S1 and S2 peptides in the HLA-DR groove is shown in Fig.4c and 4f respectively. The large binding pocket 1 harbors an aromatic residue Y73 (in S1) or F76 (in S2) making buried aromatic contacts. Pocket 4 15 is filled either with an aromatic F76 (in S1) or a hydrophobic residue V79 (in S2), while the hydrophobic residues V78 (in S1) and L81 (in S2) are pointing into pocket 6. Although both residues V79 (in S1) and D82 (in S2) bury their side chain in pocket 7, the contribution 20 to the interaction energy of S2 is more of an electrostatic nature via residue 71 of the HLA-DR  $\beta$  chain, which in most haplotypes is an arginine. The corresponding contribution of L81 (in S1) to the contact area of pocket 9 is less obvious for the S2 peptide were 25 a serine is found. Furthermore, these observations suggest that while the buried peptide residues predominantly contribute to HLA-DR anchoring, the exposed residues mediate both T-cell receptor recognition and the binding to HLA-DR.

30

#### EXAMPLE 8

##### Identification of the minimal epitopes recognized by the region(71-87) T-cell clones

To confirm that both predicted sequences were 35 functional T-cell epitopes, the minimal S1 and S2 11-mer sequences were synthesized and used in proliferation assays with the region(71-87)-specific T-cell clones.

Fig. 2 shows that clones Tc-1 to Tc-6 proliferated after being challenged with the S1 peptide, but not with the S2 peptide. Tc-7 to Tc-10 recognize the S2 peptide but not the S1 peptide. These results indicate that both S1 and S2 are functional T-cell epitopes.

#### EXAMPLE 9

##### In silico alanine scan of immunogenic regions

The contribution of each residue to the HLA-DR binding was calculated for both sequences by an in silico alanine scan. The scan of the S1 residues revealed a correlation between the loss of interaction energy and the extent of burying in HLA-DR pockets 1, 4 and 6 (Fig. 4a,c). The residues E75 or E80, respectively at positions 3 and 8 in the S1 sequence are not deeply buried in the groove, however an alanine substitution was calculated to result in a substantial loss in interaction energy. The largest contact loss between the S1 peptide and the groove was obtained with a side-chain removal of the residues occupying the pockets 1, 4 or 9 (Fig. 4b). For an alanine substitution of the residues F76, R77 and L81, at positions 1, 2 and 6 respectively in the S2 mode (Fig. 4d-f), an important loss of interaction energy and a proportional loss of contact area was observed. Alanine substitution in pocket 7 of the S2 sequence (D82) revealed no major loss in contact area, however a substantial energy loss was found, which may probably be due to the removal of the ionic interaction with residue R71 of the HLA-DR- $\beta$  chain (see also Fig.3b).

30

#### EXAMPLE 10

##### Mutagenesis in the immunogenic SakSTAR region 71-87

Altogether, these observations show that mutations at a combination of key positions lead to a reduced immunogenicity of this sequence. Changes into alanine of the important anchoring residues of both epitopes at amino acid positions Y73, F76, V78, and L81 abolished the plasminogen activating potency.

Therefore, other residues that were important for T-cell proliferation (Fig. 2) and that contributed to HLA-DR binding were targeted (Fig. 4). Residues K74 and E80 were chosen for their dual contribution in DR-  
5 anchoring and facing the TCR in the S1 binding mode. This dual contribution was also found for residue R77 in the S2 binding mode. Furthermore, residues R77 and E80 were found to be solvent exposed at an important TCR  
10 recognition position (pocket 5) in the S1 and S2 peptide, respectively. Finally, D82 was targeted for its anchoring contribution in the S2 binding mode.

The SakSTAR-mutants were engineered by the spliced overlap extension polymerase chain reaction (SOE-PCR) (Horton et al., 1989) using as template  
15 pMEX.SakSTAR-myc, encoding the wild-type SakSTAR sequence with a carboxy-terminal additional triple alanine followed by a myc sequence (Evan et al., 1985). For each mutant, the amplified product was purified and ligated into the pMEX vector (Schlott et al., 1994). All  
20 constructions were confirmed by sequencing of the entire SakSTAR-myc coding region.

The SakSTAR-variants were expressed and purified from transformed *E. coli* TG1, using experimental conditions as described (Collen et al., 1996a), followed  
25 by size exclusion chromatography using a superdex 75 column (Pharmacia, Uppsala, Sweden). The purity of the SakSTAR variants was confirmed by SDS-PAGE to be at least 98%. The following SakSTAR mutants were constructed, SakSTAR(R77A, E80A), SakSTAR(R77A, E80A, D82A) and  
30 SakSTAR(K74Q, R77S, E80S, D82S). The specific activity of all these mutants was between 50% and 100% of that of wild-type SakSTAR. Variants of wild-type staphylokinase are identified herein by the substituted amino acids in single letter symbols followed by their position number  
35 in the mature SakSTAR sequence (136 amino acids) and by the substituting amino acids in single letter symbols.

**EXAMPLE 11****Immunogenicity analysis of the redesigned 71-87 region of SakSTAR**

The S1 and S2 binding mode of the above SakSTAR  
5 mutants were remodeled in the HLA-DR binding groove. A  
loss of at least 15 kcal/mol in interaction energy and 40  
 $\text{\AA}^2$  in contact area was found for the S1 peptide of any of  
these variants. For the S2 stretch, a loss in interaction  
energy was found to be at least 10 kcal/mol, and over 100  
10  $\text{\AA}^2$  in the contact area (data not shown), indicating a  
reduced binding of the mutant peptide sequences with HLA-  
DR.

In addition, the area 69-89 of the SakSTAR  
variants were threaded through the binding groove  
15 similarly as shown in Fig. 4a to analyze the possibility  
of newly introduced epitopes. Importantly, no new binding  
motifs in any of the SakSTAR-variants were revealed. All  
region(71-87)-specific T-cell clones were tested for  
proliferation after challenge with the above described  
20 SakSTAR-mutants, and none of them showed proliferation.  
This was not due to presentation problems, because T-cell  
clones recognizing a different SakSTAR epitope were  
perfectly capable to proliferate after stimulation with  
either region(71-87) SakSTAR variant.

25

**EXAMPLE 12****Cellular immune response to the newly designed molecules**

The human T-cells used in the functional assays  
were obtained by selection and cloning procedures.  
30 Consequently, they may represent only a subset of  
region(71-87)-specific T-cells. To investigate whether a  
redesigned region actually results in a reduced  
immunogenic protein, a cellular immune response to a  
redesigned protein should be compared to that of its wild  
35 type counterpart.

However, the vast majority of humans does also  
recognize additional immunogenic SakSTAR regions  
(untouched in these SakSTAR-variants), which would

invalidate such an experiment. Therefore, 25 other healthy donors were screened for SakSTAR immunoreactivity. PBMC were thawed, washed four times in 1% human serum albumin, and cultured at  $1.8 \times 10^6$  cells/ml in RPMI 1640 supplemented with 5% human serum (Biowittaker, Walkersville, Maryland) and gentamycin with or without SakSTAR-myc for 10 days in a humidified  $\text{CO}_2$  incubator. The non-adherent cells were harvested and restimulated with no antigen, SakSTAR-myc or different peptides. For antigen presenting cells, irradiated autologous PBMC were T-cell depleted, using CD3-M450 Dynabeads (DynaI, Compi  gne, France) according manufacturer procedures (FACS analysis indicated >95% non-T-cells). The plates were incubated at 37  C under humidified atmosphere containing 5%  $\text{CO}_2$  for 5 days, and pulsed with BrdU for the last 22 to 24 hours.

Subsequently, the cells were harvested and analyzed for their BrdU content (BrdU ELISA, Boehringer Mannheim, Mannheim, Germany). A stimulation index was calculated, by dividing the OD obtained from the PBMC in response to an antigen/peptide by that of the spontaneous proliferation (no antigen) control. A value exceeding 3 was considered positive, indicating the proliferation of specific T-cells to that particular antigen/peptide.

A cellular immune response to the SakSTAR peptide(71-87) was observed in 80% of the 20 identified SakSTAR positive donors, confirming its immunodominant character.

PBMC from the 10 donors with the highest region(71-87)-specific cellular response were primed with SakSTAR-myc and subsequently challenged with different SakSTAR or region-(71-87)-mutant peptides as indicated in Fig. 5.

Although the overall cellular response to the single alanine mutated peptides was significantly reduced as compared to the wild-type peptide ( $P \leq 0.05$ ), these peptides induced a cellular response in several of the tested donors. The peptides with an alanine at positions

R77 or E80 hampered the lymphocyte proliferation of the majority of the tested donors. The relative importance of these residues was also found in the proliferation assays with the region-(71-87)-specific T-cell clones.

5                However, if SakSTAR-myc primed lymphocytes are restimulated with the double (R77A, E80A), triple (R77A, E80A, D82A), quadruple (K74Q, R77S, E80S, D82S) or quintuple (K74A, E75A, R77A, E80A, D82A) mutated peptides, none of the tested donors showed a positive  
10 cellular immune response ( $P \leq 0.001$ ). This implicates that region(71-87)-specific circulating T-lymphocytes in humans (which may have been generated by earlier infections with lysogenic Staphylococcus strains) are no longer capable of recognizing the mutated region 71-87 of  
15 any of the SakSTAR variants. Consequently, their proliferation and help to support B-lymphocytes to generate antibodies is impaired.

#### EXAMPLE 13

##### 20 Identification of critical residues in the other identified T-cell epitopes in the SakSTAR molecule

T-cell clones recognizing several of the other SakSTAR epitopes (see Table I) were analyzed in a similar manner as the region(71-87)-specific T-cell clones  
25 described in the preceding examples. The minimal sequence requirements for most SakSTAR-specific T-cell clones was determined in T-cell proliferation assays, using peptides each containing a different single alanine substitution. The results are summarized in Figure 6.

30                The T-cell clones that proliferated after a challenge with the peptide 16-SYFEPTGPYLMVNVTGV-32 could be divided into two groups, 8 T-cell clones recognized the epitope 16-26 and 10 clones did recognize the SakSTAR sequence 23-33. An alanine substitution at F18, or E19  
35 abrogated proliferation of all isolated region(16-26)-specific T-cell clones, whereas most T-cell clones could no longer proliferate if Y17, or Y24 was mutated into an alanine. Side-chain removal of P20 or G23 affected the T-

cell proliferation of more than half of this group of T-cell clones. All isolated region(23-33)-specific T-cell clones were found sensitive for an alanine substitution at positions Y24, M26, or N28, whereas an alanine substitution of T30 or G31 abrogated proliferation of the majority of the isolated region(16-26)-specific T-cell clones.

Based on these data combined with the calculated residue preference matrices several SakSTAR-mutants were constructed: SakSTAR(P20Y, Y24A), SakSTAR(P20Y, Y24S), SakSTAR(E19D), SakSTAR(Y17L), SakSTAR(F18L), SakSTAR(F18E), SakSTAR(G22S), SakSTAR(G22S, P23G), SakSTAR(N28S), and SakSTAR(V29L, L127V). All these SakSTAR-mutants had a reduced immunogenic profile for the region(16-32) specific T-cell clones.

Analysis of 14 T-cell clones specific for the SakSTAR peptide 56-TKEKIEYYVEWALDATA-72 was performed. An alanine substitution at residues Y62, E65 or W66 resulted in the loss of proliferation of the vast majority of these region-specific T-cell clones. Approximately half of these T-cell clones were found sensitive for side chain removal of residues E61, Y63, V64, L68 or D69. Based on these data combined with the calculated residue preference matrices several SakSTAR-mutants were constructed, however all had lost their thrombolytic activity. The 56-72 immunogenic region of SakSTAR is part of the activation epitope as defined by Jespers et al. Mutation of one of the activation epitope residues into most other residue types creates a biological inactive molecule (Jespers et al (1999)).

Nine T-cell clones specific for the SakSTAR peptide 106-ITEKGFVVPDLSEHIKN-122 were also analyzed. Alanine substitution at positions P114, L116, E118, or H119 abolished proliferation of the majority of the region(106-122)-specific T-cell clones. Side chain removal of F111 or D115 affected the proliferative capacity of approximately half of these T-cell clones.

Based on these data combined with the calculated residue preference matrices several SakSTAR-mutants were constructed: SakSTAR(H119A), SakSTAR(H119S), SakSTAR(V89L, L116Y), SakSTAR(V89L, L116T),  
5 SakSTAR(V112T), SakSTAR(V112S), SakSTAR(D115N), and SakSTAR(E118S). All these SakSTAR-mutants had a significantly reduced immunogenic profile for the region(106-122) specific T-cell clones. Although an alanine change at V112 had an effect of only 11% of the  
10 region-specific T-cell clones, interestingly the biologically active mutants SakSTAR(V112T) and SakSTAR(V112S) could not induce proliferation in any of the region(106-122)-specific T-cell clones. This was not due to the construction (as confirmed by sequencing) or  
15 purity of the isolated SakSTAR mutant, because T-cell proliferation of other SakSTAR-specific T-cell clones could be induced using these mutants comparable to that with wild-type SakSTAR.

The following combinatorial mutants have been  
20 constructed and isolated; SakSTAR(V112T, H119A), SakSTAR(V112T, H119S), SakSTAR(V112T, E118S, H119S), and SakSTAR(V112T, H119S, K130Y). These thrombolytically active mutants lost their capacity to induce the region(106-122)-specific T-cell clone proliferation,  
25 indicating that the immunogenicity of SakSTAR region 106-122 was eliminated.

Finally, 7 T-cell clones recognizing the SakSTAR peptide 120-IKNPGFNLITKVVIEKK-136 were analyzed for their minimal sequence requirements. Alanine  
30 substitution at positions G124, F125, N126, or L127 abolished proliferation of the majority of the region(120-136)-specific T-cell clones. Side chain removal of I128, T129, K130, V131, or V132 affected the proliferative capacity of approximately half of these T-  
35 cell clones. Based on these data combined with the calculated residue preference matrices, two biologically active SakSTAR-mutants were constructed. The mutant SakSTAR(R77E, E134R) has been tested in proliferation

assays using several region(120-136)-specific T-cell clones and some region(71-89)-specific T-cell clones. It was found that this mutant could support the proliferation of some, but not all T-cell clones from both specificities, indicating that two SakSTAR regions had a reduced immunogenic profile. Although the mutation of residue K130 into alanine in the SakSTAR120-136 peptide did only have an effect on approximately half of the isolated region(120-136)-specific T-cell clones, this residue was targeted. Computer modeling supplemented with the residue preference matrix revealed that if an Y replaces residue K130 within this epitope (GFLITYVVIE), the interaction energy between this mutant-epitope and the HLA-DR binding groove is so high, that binding within the groove is predicted to be impossible. Therefore, mutant SakSTAR(K130Y) was constructed, expressed and purified, and was found to have a thrombolytic activity similar to that of wild-type SakSTAR. The region(120-136)-specific T-cell clones were tested with this SakSTAR-mutant, and none of them could proliferate, suggesting the epitope was no longer functional. Therefore, mutation of residue K130 of SakSTAR into Y is the ultimate mutation, because the presentation of this redesigned region is completely lost.

25

Altogether, these analyses demonstrate that the immunogenicity of a heterologous protein can be reduced by the removal of functional T-cell epitopes. As a consequence, the elimination of a combination of immunogenic regions will further reduce the T-cell reactivity, and therefore the overall immunogenicity of a combined mutant protein. Furthermore, the rational approach combining functional assays with mathematical models may lead to the precise removal of HLA-DR anchoring residues, affecting the presentation of T-cell epitopes and the initiation of T-cell reactivity.

## REFERENCES

- Behnke, D., and Gerlach, D. (1987). Cloning and expression in *Escherichia coli*, *Bacillus subtilis*, and *Streptococcus sanguis* of a gene for staphylokinase--a bacterial plasminogen activator. *Mol Gen Genet* 210, 528-534.
- Brooks, B. R., Bruccoleri, R., Olafson, D., States, D. J., Swaminathan, S., and Karplus, M. (1983). CHARMM: A Program for macromolecular energy, minimization, and dynamics calculations. *J. Comput. Chem* 4, 187-217.
- Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993). Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. *Nature* 364, 33-39.
- Buyse, I., Decorte, R., Baens, M., Cuppens, H., Semana, G., Emonds, M. P., Marynen, P., and Cassiman, J. J. (1993). Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. *Tissue Antigens* 41, 1-14.
- Collen, D. (1998). Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. *Nat Med* 4, 279-284.
- Collen, D., Bernaerts, R., Declerck, P., De Cock, F., Demarsin, E., Jenne, S., Laroche, Y., Lijnen, H. R., Silence, K., and Verstreken, M. (1996a). Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. *Circulation* 94, 197-206.
- Collen, D., Moreau, H., Stockx, L., and Vanderschueren, S. (1996b). Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. *Circulation* 94, 207-216.

- Collen, D., Zhao, Z. A., Holvoet, P., and Marynen, P. (1992). Primary structure and gene structure of staphylokinase. *Fibrinolysis* 6, 226-231.
- 5 De Maeyer, M., Desmet, J., and Lasters, I. (1997). All in one: a highly detailed rotamer library improves both accuracy and speed in the modelling of side chains by dead-end elimination. *Fold Des* 2, 53-66.
- 10 Delhaise, P., Bardiaux, M., and Wodak, S. (1984). Interactive computer animation of macromolecules. *J Mol Graphics* 2, 103-106.
- Desmet, J., De Maeyer, M., Hazes, B., and Lasters, I. (1992). The dead-end elimination theorem and its use in protein side-chain positioning. *Nature* 356, 539-542.
- 15 Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, J. M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol Cell Biol* 5, 3610-3616.
- 20 Hiemstra, H. S., Duinkerken, G., Benckhuijsen, W. E., Amons, R., de Vries, R. R., Roep, B. O., and Drijfhout, J. W. (1997). The identification of CD4+ T-cell epitopes with dedicated synthetic peptide libraries. *Proc Natl Acad Sci U S A* 94, 10313-10318.
- 30 Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and Pease, L. R. (1989). Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* 77, 61-68.
- Jespers, L., Vanwetswinkel, S., Lijnen, R., Van Herzele, N., Van Hoef, B., Demarsin, E., Collen, D., and De Maeyer, M. (1999). Structural and functional basis of plasminogen activation by staphylokinase. *Thrombosis Hemostasis* 81, 479-485.

- Koradi, R., Billeter, M., and Wuthrich, K. (1996).  
MOLMOL: a program for display and analysis of  
macromolecular structures. *J Mol Graphics* 14, 51-55.
- 5 Miller, G., and Lipman, M. (1973). Release of infectious  
Epstein-Barr virus by transformed marmoset leukocytes.  
*Proc Natl Acad Sci U S A* 70, 190-194.
- Sako, T., and Tsuchida, N. (1983). Nucleotide sequence of  
10 the staphylokinase gene from *Staphylococcus aureus*.  
*Nucleic Acids Res* 11, 7679-7693.
- Schlott, B., Hartmann, M., Guhrs, K. H., Birch-  
Hirschfeld, E., Pohl, H. D., Vanderschueren, S., Van de  
15 Werf, F., Michoel, A., Collen, D., and Behnke, D. (1994).  
High yield production and purification of recombinant  
staphylokinase for thrombolytic therapy. *Biotechnology (N  
Y)* 12, 185-189.
- 20 Warshel, A., and Levitt, M. (1976). Theoretical studies  
of enzymic reactions: dielectric, electrostatic and  
steric stabilization of the carbonium ion in the reaction  
of lysozyme. *J Mol Biol* 103, 227-249.
- 25 Wodak, S. J., De Coen, J. L., Edelstein, S. J., Demarne,  
H., and Beuzard, Y. (1986). Modification of human  
hemoglobin by glutathione. III. Perturbations of  
hemoglobin conformation analyzed by computer modeling. *J  
Biol Chem* 261, 14717-14724.

## CLAIMS

1. Method for reducing the immunogenicity of a peptide or protein, which method comprises the steps of:
- 5 a) designing a series of overlapping test peptides each having an amino acid sequence that corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced;
- 10 b) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);
- c) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);
- 15 d) repeating step b) and optionally step c) with the modified test peptides until one or more of the T-cell epitopes originally comprised therein are significantly reduced or eliminated;
- e) modifying the amino acid sequence of the
- 20 peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides to produce a modified peptide or protein.
2. Method as claimed in claim 1, wherein the
- 25 identification of test peptides comprising a T-cell epitope is performed by means of a functional T-cell assay in which proliferation of one or more T-cell clones after stimulation of the T-cell clone(s) with one of the test peptides means that the said test peptide comprises
- 30 a T-cell epitope.
3. Method as claimed in claim 1, wherein the identification of test peptides comprising a T-cell epitope is performed by means of a functional T-cell assay in which proliferation of one or more T-lymphocytes
- 35 as present in the circulation of humans (PBMC) after stimulation of the PBMC with one of the test peptides means that the said test peptide comprises a T-cell epitope.

4. Method as claimed in claim 1, wherein the identification of test peptides comprising a T-cell epitope is performed by determining the interaction energy of the test peptide with the binding groove of one or more HLA-DR haplotypes by means of computer modeling, in which test peptide(s) are identified as comprising a T-cell epitope when according to their interaction energy they fit into the HLA-DR binding groove.

5. Method as claimed in claim 1, wherein the identification of test peptides comprising a T-cell epitope is performed by a combination of the following tests:

a) a functional T-cell assay in which proliferation of one or more T-cell clones after stimulation of the T-cell clone(s) with one of the test peptides means that the said test peptide comprises a potential T-cell epitope; and/or

b) a functional T-cell assay in which proliferation of one or more T-lymphocytes as present in the circulation of humans (PBMC) after stimulation of the PBMC with one of the test peptides means that the said test peptide comprises a T-cell epitope; and

c) determining the interaction energy of the said test peptide with the binding groove of one or more HLA-DR haplotypes by means of computer modeling, in which the test peptide is identified as comprising a potential T-cell epitope when according to its interaction energy it fits into the HLA-DR binding groove, wherein a test peptide is considered to comprise a T-cell epitope if it is identified in test a) and/or b) and c).

6. Method as claimed in claims 1-5, further comprising one or more repetitions of steps b) to e) with the modified peptide or protein instead of the test peptides.

7. Method as claimed in claims 1-6, which method comprises the steps of:

a) designing a series of overlapping test peptides each having an amino acid sequence that

corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced;

b) identifying which of the test peptides of  
5 the series comprises one or more T-cell epitope(s);

c) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);

d) testing the modified peptides for their  
10 potential to activate T-cells and induce proliferation of either T-cell clones or T-lymphocytes as present in the circulation of humans (PBMC);

e) modifying the amino acid sequence of the peptide or protein of which the immunogenicity is to be  
15 reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides;

f) construction and purification of the modified peptide or protein of which the immunogenicity is to be reduced in a suitable host, and testing its  
20 biological activity;

g) repeating step c-f) with the modified test peptides or protein until one or more of the T-cell epitopes originally comprised therein are significantly reduced or eliminated and contemplating the biological  
25 activity.

8. Method for reducing the immunogenicity of a peptide or protein, which method comprises the steps of:

a) designing a series of overlapping test peptides each having an amino acid sequence that  
30 corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced;

b) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);

35 c) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);

d) testing the modified peptides for their potential to activate T-cells and induce proliferation of either T-cell clones or T-lymphocytes as present in the circulation of humans (PBMC);

5 e) modifying the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides;

f) construction and purification of the  
10 modified peptide or protein of which the immunogenicity is to be reduced in a suitable host, and testing its biological activity;

g) repeating step c-f) with the modified test peptides or protein until one or more of the T-cell  
15 epitopes originally comprised therein are significantly reduced or eliminated and contemplating the biological activity.

9. Method as claimed in claim 7 and 8, wherein the step of identification of which of the test peptides  
20 of the series comprises one or more T-cell epitope(s) is performed as described in claims 2, 3 or 4.

10. Method as claimed in claims 1-9, wherein the T-cell epitopes are eliminated by minimal residue/region mutagenesis.

25 11. Method as claimed in claims 1-10, wherein the T-cell epitopes are eliminated by deletion or insertion of residues in the identified T-cell epitopes.

12. Method as claimed in claims 1-11, wherein the T-cell epitopes are eliminated by substitution with  
30 human sequences, or human homologous sequences.

13. Method as claimed in claims 1-12, wherein the T-cell epitopes are eliminated by enhancing the sensitivity of the identified T-cell epitopes for proteolytic endosomal enzymes.

35 14. Method as claimed in claims 1-13, further comprising the identification and removal of HLA-DR anchoring residues of the peptide or protein to reduce the immunogenicity thereof.

15. Method as claimed in claims 1-14, wherein the biological activity of the protein or peptide with reduced immunogenicity is tested after modification of the amino acid sequence of the protein or peptide.

5           16. Method for producing a peptide or protein having a reduced immunogenicity in comparison to the wild type peptide or protein, comprising the following steps:

          a) providing a DNA sequence encoding at least the amino acid sequence of the peptide or protein that  
10 provides for the biological activity thereof;  
          b) identifying one or more of the T-cell epitopes comprised in the amino acid sequence of the wild type peptide or protein by:

          1) designing a series of overlapping test  
15 peptides each having an amino acid sequence that corresponds with part of the amino acid sequence of the peptide or protein;

          2) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);

20           3) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);

          4) repeating step 2) and optionally step 3) with the modified test peptides until one or more of  
25 the T-cell epitopes originally comprised therein are significantly reduced or eliminated;

          c) modifying the DNA sequence to introduce the modifications to the T-cell epitope(s) in the amino acid sequence encoded thereby;

30           d) introducing the DNA sequence into a host organism;

          e) culturing the host organism under conditions allowing expression of the modified peptide or protein;  
and

35           f) isolating the peptide or protein having a reduced immunogenicity from the host organism.

17. Method for producing a peptide or protein having a reduced immunogenicity in comparison to the wild type peptide or protein, comprising the following steps:

- a) providing a DNA sequence encoding at least  
5 the amino acid sequence of the peptide or protein that provides for the biological activity thereof;
- b) identifying and modifying one or more of the T-cell epitopes comprised in the amino acid sequence of the wild type peptide or protein by:
  - 10 1) identifying which of the test peptides of the series comprises one or more T-cell epitope(s);
  - 2) modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s);
  - 15 3) testing the modified peptides for their potential to activate T-cells and induce proliferation of either T-cell clones or T-lymphocytes as present in the circulation of humans (PBMC);
  - 4) modifying the amino acid sequence of  
20 the peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides;
  - 5) construction and purification of the  
25 modified peptide or protein of which the immunogenicity is to be reduced in a suitable host, and testing its biological activity;
  - 6) repeating step 2-5) with the modified test peptides or protein until one or more of the T-cell  
30 epitopes originally comprised therein are significantly reduced or eliminated and contemplating the biological activity;
- c) modifying the DNA sequence to introduce the modifications to the T-cell epitope(s) in the amino acid  
35 sequence encoded thereby;
- d) introducing the DNA sequence into a host organism;

e) culturing the host organism under conditions allowing expression of the modified peptide or protein; and

f) isolating the peptide or protein having a  
5 reduced immunogenicity from the host organism.

18. DNA construct encoding the modified DNA sequence as defined in claim 16 or 17.

19. Host organism, comprising the DNA construct as claimed in claim 18.

10 20. Modified peptide or protein showing a reduced T-cell based immunogenicity as compared to the wild type peptide or protein and differing from the wild type peptide or protein in at least one amino acid substitution, deletion or insertion that leads to the  
15 elimination of at least one T-cell epitope but does not lead to loss of the biological activity of the peptide or protein.

21. Modified peptide or protein as claimed in claim 20, obtainable by means of the method as claimed in  
20 claims 1-17.

22. Modified peptide or protein as claimed in claims 20 and 21 for use in treatment, diagnosis or prophylaxis.

23. Use of a modified peptide or protein as  
25 claimed in claims 20 and 21 for the preparation of a pharmaceutical composition for treatment, diagnosis or prophylaxis of a human subject.

24. Pharmaceutical composition comprising a modified peptide or protein as claimed in claims 20 and  
30 21 together with a pharmaceutically acceptable carrier, diluents or excipient.

25. Modified peptide or protein as claimed in claim 20 or 21, which protein is staphylokinase.

26. Staphylokinase variants in which one or  
35 more of the following immunogenic regions are modified such that the T cell epitopes contained therein are eliminated:

1-SSSFDKGKYKKGDDASY-17,

16-SYFEPTGPLYLMVNVTVG-32,  
56-TKEKIEYYVEWALDATA-72,  
71-TAYKEFRVVELDPSAKI-87,  
106-ITEKGFVVPDLSEHIKN-122, and  
5 120-IKNPGFNLITKVVIEKK-136.

27. Staphylokinase variants as claimed in claim 26 with reduced T-cell reactivity as compared to wild type staphylokinase, but retaining its biological activity, which variants have the amino acid sequence depicted in Figure 1 with one or more of the following amino acid substitutions in one or more of the following immunogenic region:

a) in the immunogenic region comprising SakSTAR residues 16-32 the substitutions Y17L; F18L; F18E; E19D;  
15 P20Y, Y24A; P20Y, Y24S; G22S; G22P, P23G; or N28S;

b) in immunogenic region comprising SakSTAR residues 71-82 the substitutions F76W, V79Y, D82A; R77A, E80A; R77S, E80S; R77A, E80A, D82A; K74Q, R77S, E80S; K74Q, R77S, E80S, D82G; K74Q, R77S, E80S, D82A; K74Q,  
20 R77S, E80A, D82A; K74Q, R77A, E80S, D82A; K74Q, R77S, E80S, D82S; or V79Y, D82A;

c) in immunogenic region comprising SakSTAR residues 106-122 the substitutions V112T; V112S; D115N; E118S; H119A; H119S; V89L, L116Y; V89L, L116T;  
25 V112T, H119S; V112T, H119A; or V112T, E118S, H119S;

d) in immunogenic region comprising SakSTAR residues 120-136, the substitution K130Y.

28. Staphylokinase variants as claimed in claim 27, having a combination of one or more of the mutations  
30 listed in claim 27.

29. Staphylokinase variants as claimed in claim 28, having one of the following combination of mutations V112T, H119S, K130Y; R77E, E134R; V29L, L127V; K74Q, R77E, E80S, D82S, E134R; R77S, E80S, V112T, H119S; R77S,  
35 E80S, V112T, H119S, K130Y; R77A, E80A, V112T, H119S; R77A, E80A, V112T, H119S, K130Y; K74Q, R77S, E80S, V112T, H119S; K74Q, R77S, E80S, V112T, H119S, K130Y; K74Q, R77S,

E80S, D82S, V112T, H119S; or K74Q, R77S, E80S, D82S, V112T, H119S, K130Y.

30. Staphylokinase variant selected from the group consisting of SakSTAR(P20Y, Y24A), SakSTAR(P20Y, Y24S), SakSTAR(E19D), SakSTAR(Y17L), SakSTAR(F18L), SakSTAR(F18E), SakSTAR(G22S), SakSTAR(G22S, P23G), SakSTAR(N28S), SakSTAR(V29L, L127V), SakSTAR(R77E, E134R), SakSTAR(K74Q, R77E, E80S, D82S, E134R), sakSTAR(K74Q, R77E, E80S, D82S, V112T, H119S, E134R), 10 sakSTAR(K74Q, R77E, E80S, D82S, V112T, H119S, E134R, K130Y), SakSTAR(R77S, E80S, V112T, H119S), SakSTAR(R77S, E80S, V112T, H119S, K130Y), SakSTAR(R77A, E80A, V112T, H119S), SakSTAR(R77A, E80A, V112T, H119S, K130Y), SakSTAR(K74Q, R77S, E80S, V112T, H119S), SakSTAR(K74Q, 15 R77S, E80S, V112T, H119S, K130Y), SakSTAR(K74Q, R77S, E80S, D82S, V112T, H119S), SakSTAR(K74Q, R77S, E80S, D82S, V112T, H119S, K130Y), SakSTAR(V112T, H119A), SakSTAR(V112T, H119S), SakSTAR(V112T, E118S, H119S), SakSTAR(V112T, H119S, K130Y), SakSTAR(V112T), 20 SakSTAR(V112S), SakSTAR(H119A), SakSTAR(H119S), SakSTAR(V89L, L116Y), SakSTAR(V89L, L116T), SakSTAR(V112T), SakSTAR(V112S), SakSTAR(D115N), SakSTAR(E118S), SakSTAR(K130Y).

31. Staphylokinase variant as claimed in claims 25 25-30 for use in treatment, diagnosis or prophylaxis.

32. Use of a staphylokinase variant as claimed in claims 25-30 for the preparation of a pharmaceutical composition for treatment, diagnosis or prophylaxis of a human subject.

30 33. Pharmaceutical composition comprising a staphylokinase variant as claimed in claims 25-30 together with a pharmaceutically acceptable carrier, diluents or excipient.

1/7

1 | 10 | 20 | 30 | 40 | 50 |  
| SSSFDK GK YK | KGDDASYFEP | TGPYLMVNVT | GVDSKGNELL | SPHYVEFFPIK |  
60 | 70 | 80 | 90 | 100 |  
| PGTTLTKEKI | EYYVEWALDA | TAYKEFRVVE | LDPSAKIEVT | YYDKNKKKEE |  
110 | 120 | 130 | 136 |  
| TKSFPITEKG | FVVPDLSEHI | KNPGFNLTITK | VWIEKK |

FIG. 1






FIG. 2

3/7

FIG. 3A

4/7




FIG. 4A

5/7





FIG. 4B

6/7

**FIG. 5**

SakSTAR T  
cell

7/7

total of  
epitope-  
specific  
T-cell clones  
tested

16	S	Y	F	E	P	T	G	P	Y	L	M	26	
	100	12.5	0	0	37.5	87.5	37.5	75	12.5	62.5	87.5		8
	■				△	■	△	■		⊕	■		
23	P	Y	L	M	V	N	V	T	G	V	D	33	
	100	0	60	0	70	0	50	20	30	50	nd		10
	■		⊕		⊕		⊕		△	⊕			
61	E	Y	Y	V	E	W	A	L	D	A	T	71	
	57	0	43	50	10	14	nd	43	43	nd	86		14
	⊕		△	⊕				△	△		■		
72	A	Y	K	E	F	R	V	V	E	L	D	82	
	nd	52	0	29	38	14	33	81	14	90	67		21
		⊕		△	△		△	■		■	⊕		
75	E	F	R	V	V	E	L	D	P	S	A	85	
	92	50	33	8	67	0	58	17	41	83	nd		12
	■	⊕	△		⊕		⊕		△	■			
110	G	F	V	V	P	D	L	S	E	H	I	120	
	89	56	89	78	33	67	11	100	33	0	89		9
	■	⊕	■	■	△	⊕		■	△		■		
124	G	F	N	L	I	T	K	V	V	I	E	134	
	14	29	29	14	43	43	57	43	57	86	86		7
		△	△		△	△	⊕	△	⊕	■	■		

FIG. 6

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40281 A3**

- (51) International Patent Classification<sup>7</sup>: C07K 14/31, C12N 15/31, A61K 38/16
- (21) International Application Number: PCT/EP00/12299
- (22) International Filing Date: 1 December 2000 (01.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
99204093.1 2 December 1999 (02.12.1999) EP
- (71) Applicant (for all designated States except US): THROMB-X N.V. [BE/BE]; Leopold-I-straat 1, bus 21, B-3000 Leuven (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WARMERDAM, Petronella, Adriana, Maria [NL/BE]; Ploegstaart 1, NL-3010 Kessel-Lo (BE). PLAISANCE, Stéphane, Daniel, Noël, Georges, Henri [BE/BE]; A. Woutersstraat 61, B-3012 Wilsele (BE). COLLEN, Désiré, José [BE/GB]; 28 Collingham Gardens, London SW5 0HN (GB). DE MAEYER, Marc, Cyriel, Hilda [BE/BE]; Keienveld 2, B-1702 Groot-Bijgaarden (BE).
- (74) Agent: VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
20 December 2001

[Continued on next page]

(54) Title: METHOD FOR REDUCING THE IMMUNOGENICITY OF HETEROLOGOUS PROTEINS BY ELIMINATION OF T-CELL EPITOPES

```

1      10      20      30      40      50
|      |      |      |      |      |
SSSFDKGYK KGDDASYFEP TGPYLMVNT GVDSKGNELL SPHYVEFPIK

      60      70      80      90      100
      |      |      |      |      |
PGTTLTKEKI EYYVEWALDA TAYKEFRVVE LDPSAKIEVT YYDKNKKKEE

      110      120      130      136
      |      |      |      |
TKSFPITEKG FVVPDLSEHI KNPGFNLITK VVIEKK

```

(57) Abstract: The present invention provides a method for reducing the immunogenicity of a peptide or protein, which method comprises the steps of designing a series of overlapping test peptides each having an amino acid sequence that corresponds with part of the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced; identifying which of the test peptides of the series comprises one or more T-cell epitope(s); modifying the amino acid sequence of one or more of the test peptides comprising one or more T-cell epitope(s); repeating some of the steps with the modified test peptides until one or more of the T-cell epitopes originally comprised therein are significantly reduced or eliminated; modifying the amino acid sequence of the peptide or protein of which the immunogenicity is to be reduced according to the T-cell eliminating modifications made in the amino acid sequence of the test peptides to produce a modified peptide or protein. The invention also relates to the modified peptides and proteins thus obtained.



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

Int: ational Application No

PCT/EP 00/12299

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K14/31 C12N15/31 A61K38/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 53038 A (GENENCOR INT) 21 October 1999 (1999-10-21)	1,3,7,9, 10,12,16
Y	page 2-10; examples 1,2	1-17
X	WO 98 52976 A (BIOVATION LTD ;CARR FRANCIS J (GB)) 26 November 1998 (1998-11-26)	1,4,6, 8-10,12, 14-17
Y	page 2, line 23 -page 5, line 5 page 7, line 20 -page 8, line 10; examples 1,2,5,7	1-17
P,X	WO 00 34317 A (ADAIR FIONA SUZANNE ;CARR FRANCIS JOSEPH (GB); HAMILTON ANITA ANNE) 15 June 2000 (2000-06-15) page 3, line 23 -page 9, line 15; example 3	1-17
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 July 2001

Date of mailing of the international search report

0 8. 08. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Steffen, P

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/12299

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GUNDLACH B R ET AL: "Determination of T cell epitopes with random peptide libraries"</p> <p>JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 192, no. 1, 10 June 1996 (1996-06-10), pages 149-155, XP004020829</p> <p>ISSN: 0022-1759</p> <p>page 149 -page 150, left-hand column, paragraph 2</p> <p style="text-align: center;">---</p>	
A	<p>STAUSS H J ET AL: "INDUCTION OF CYTOTOXIC T LYMPHOCYTES WITH PEPTIDES IN VITRO: IDENTIFICATION OF CANDIDATE T-CELL EPITOPES IN HUMAN PAPILLOMA VIRUS"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 89, 1 September 1992 (1992-09-01), pages 7871-7875, XP002031413</p> <p>ISSN: 0027-8424</p> <p>page 7871 -page 7872, left-hand column, paragraph 1</p> <p style="text-align: center;">---</p>	
A	<p>ERB K J ET AL: "Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice"</p> <p>VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 7, 1 April 1998 (1998-04-01), pages 692-697, XP004112257</p> <p>ISSN: 0264-410X</p> <p>page 693 -page 694</p> <p style="text-align: center;">---</p>	
A	<p>CHAUX PASCAL ET AL: "Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes."</p> <p>JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 5, 1 March 1999 (1999-03-01), pages 767-777, XP002165455</p> <p>ISSN: 0022-1007</p> <p>page 768 -page 769</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	

## INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/EP 00/12299

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MANICI SIMONA ET AL: "Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11."</p> <p>JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 5, 1 March 1999 (1999-03-01), pages 871-876, XP002165456 ISSN: 0022-1007 page 871 -page 873, left-hand column</p>	
A	<p>COLLEN ET AL: "Thrombolytic properties of poorly immunogenic variants of recombinant staphylokinase"</p> <p>FIBRINOLYSIS AND PROTEOLYSIS,US,NEW YORK, NY, vol. 12, no. SUPPL. 01, June 1998 (1998-06), page 30 XP002111034 ISSN: 1369-0191 the whole document</p>	26-33
A	<p>COLLEN D ET AL: "Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization"</p> <p>CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 94, no. 2, 15 July 1996 (1996-07-15), pages 197-206, XP002111037 ISSN: 0009-7322 the whole document</p>	26-33
A	<p>COLLEN D ET AL: "Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction"</p> <p>CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 94, no. 2, 15 July 1996 (1996-07-15), pages 207-216, XP002111036 ISSN: 0009-7322 the whole document</p>	26-33
A	<p>COLLEN D ET AL: "Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns"</p> <p>CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 95, no. 2, 21 January 1997 (1997-01-21), pages 455-462, XP002111035 ISSN: 0009-7322 the whole document</p>	26-33
	---	
	---/---	

# INTERNATIONAL SEARCH REPORT

In tional Application No

PCT/EP 00/12299

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COLLEN D ET AL: "Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency" CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 95, no. 2, 21 January 1997 (1997-01-21), pages 463-472, XP002111038 ISSN: 0009-7322 the whole document	26-33
P,A	LAROCHE YVES ET AL: "Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes." BLOOD, vol. 96, no. 4, 15 August 2000 (2000-08-15), pages 1425-1432, XP002172610 ISSN: 0006-4971 the whole document	26-33

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 00/12299

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 18-25  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-24

Methods for reducing the immunogenicity of a peptide or a protein and methods for producing a peptide or a protein with reduced immunogenicity. Furthermore, general DNA constructs encoding an unspecified protein with reduced immunogenicity, host cells, unspecified modified peptides or proteins with reduced immunogenicity, uses and compositions thereof.

2. Claims: 25-33

Unspecified staphylokinase variants in which at least one T-cell epitope has been removed in order to reduce the immunogenicity, specified staphylokinase variants in which T-cell epitopes have been removed, uses and pharmaceutical compositions thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18-25

Present claims 18-24 relate to compounds e.g. general DNA constructs and unspecified modified peptides, as well as uses thereof, said compounds being only defined by reference to a desirable characteristic or property, namely that said compounds have been obtained by the (general) methods of the application. This same is valid for the modified staphylokinase peptides or proteins of claim 25, which are only defined by the method of obtention.

Hence, claims 18-25 lack clarity within the meaning of Article 6 PCT, and the inferred compounds lack technical features in such way, that a meaningful search for claims 18-25 is not possible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/12299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9953038 A	21-10-1999	AU 3645499 A BR 9909640 A CN 1297484 T EP 1073754 A NO 20005153 A US 6218165 B	01-11-1999 19-12-2000 30-05-2001 07-02-2001 11-12-2000 17-04-2001
WO 9852976 A	26-11-1998	AU 7539398 A EP 0983303 A GB 2339430 A	11-12-1998 08-03-2000 26-01-2000
WO 0034317 A	15-06-2000	AU 1667600 A CN 1294596 T EP 1051432 A AU 4635699 A	26-06-2000 09-05-2001 15-11-2000 24-01-2000

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**